DE69315440T2 - Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie - Google Patents

Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie

Info

Publication number
DE69315440T2
DE69315440T2 DE69315440T DE69315440T DE69315440T2 DE 69315440 T2 DE69315440 T2 DE 69315440T2 DE 69315440 T DE69315440 T DE 69315440T DE 69315440 T DE69315440 T DE 69315440T DE 69315440 T2 DE69315440 T2 DE 69315440T2
Authority
DE
Germany
Prior art keywords
met
hgf
antibody
substance
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69315440T
Other languages
English (en)
Other versions
DE69315440D1 (de
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Army
Original Assignee
US Department of Health and Human Services
US Department of Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Army filed Critical US Department of Health and Human Services
Publication of DE69315440D1 publication Critical patent/DE69315440D1/de
Application granted granted Critical
Publication of DE69315440T2 publication Critical patent/DE69315440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69315440T 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie Expired - Fee Related DE69315440T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18
PCT/US1993/008531 WO1994006909A2 (en) 1992-09-18 1993-09-15 A method of preventing tumor metastasis

Publications (2)

Publication Number Publication Date
DE69315440D1 DE69315440D1 (de) 1998-01-08
DE69315440T2 true DE69315440T2 (de) 1998-07-09

Family

ID=25483898

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69315440T Expired - Fee Related DE69315440T2 (de) 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
DE69334159T Expired - Lifetime DE69334159D1 (de) 1992-09-18 1993-09-15 Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69334159T Expired - Lifetime DE69334159D1 (de) 1992-09-18 1993-09-15 Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen

Country Status (10)

Country Link
EP (2) EP0662130B1 (de)
JP (2) JP3553936B2 (de)
AT (2) ATE368738T1 (de)
AU (1) AU675968B2 (de)
CA (1) CA2144856A1 (de)
DE (2) DE69315440T2 (de)
DK (1) DK0662130T3 (de)
ES (1) ES2112997T3 (de)
GR (1) GR3026165T3 (de)
WO (1) WO1994006909A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
JP2001505995A (ja) * 1996-11-05 2001-05-08 スミスクライン・ビーチャム・コーポレイション 肝細胞成長因子アンタゴニスト
AU1465400A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of inhibitors of the hgf-met-upa-plasmin network using a novel cellular assay
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
WO2001034650A1 (en) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
AU2001277854B2 (en) * 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
MX2007001470A (es) 2004-08-05 2007-03-26 Genentech Inc Antagonistas anti-cmet humanizados.
WO2006105511A1 (en) 2005-03-31 2006-10-05 The General Hospital Corporation Monitoring and modulating hgf/hgfr activity
RU2403261C2 (ru) 2005-04-15 2010-11-10 Дженентек, Инк. Варианты бета-цепи hgf
CA2646620C (en) * 2006-03-20 2015-07-14 Seikagaku Corporation Therapeutic agent for rheumatoid arthritis
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
EP2635602B1 (de) 2010-11-03 2016-09-07 Argen-X Nv Anti-c-met-antikörper
CA2832113C (en) 2011-04-02 2020-07-21 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
MX2013014687A (es) 2011-06-30 2014-02-17 Genentech Inc Formulaciones de anticuerpo anti-c-met.
EP2773660A2 (de) 2011-11-03 2014-09-10 Argen-X B.V. Chimäre mensch-kamel-antigene und ihre verwendung
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3122900A1 (de) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
CA2118012A1 (en) * 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants

Also Published As

Publication number Publication date
ATE160585T1 (de) 1997-12-15
AU675968B2 (en) 1997-02-27
AU4855593A (en) 1994-04-12
JP2004002440A (ja) 2004-01-08
DE69334159D1 (de) 2007-09-13
WO1994006909A2 (en) 1994-03-31
DK0662130T3 (da) 1998-08-10
EP0805203A1 (de) 1997-11-05
JP3553936B2 (ja) 2004-08-11
EP0662130A1 (de) 1995-07-12
EP0805203B1 (de) 2007-08-01
GR3026165T3 (en) 1998-05-29
CA2144856A1 (en) 1994-03-31
EP0662130B1 (de) 1997-11-26
ATE368738T1 (de) 2007-08-15
WO1994006909A3 (en) 1994-05-26
ES2112997T3 (es) 1998-04-16
JPH08504093A (ja) 1996-05-07
DE69315440D1 (de) 1998-01-08

Similar Documents

Publication Publication Date Title
DE69315440D1 (de) Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
ATE236271T1 (de) Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DE69736197D1 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69907418D1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69211899D1 (de) Siloxan modifizierter Polyester zur Behandlung von Fasern
DE69306915D1 (de) Kombination zur Detektion von Weichgewebeanomalien
DE69314234T2 (de) Konservierte Polysiloxanemulsion zur Behandlung von Geweben
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
FI982745A (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt"
DE69328091T2 (de) Bindungspeptide zur interaktion mit wachstumsfaktoren als liganden des rezeptors des epidermiswachstumsfactor und des erbb-2-rezeptor
DE69836758D1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69127344D1 (de) Katalysierte Äquilibrierung von Polyorganosiloxanen und Verfahren zur Herstellung von Cyclosiloxanen
ATE237691T1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
DE69606321T3 (de) Verwendung von 2-Ethylhexyl-alpha-cyano-beta, beta-diphenylacrylat zur Verbesserung der Lichtstabilität von p-Methylbenzylidencampher
DE59707382D1 (de) Verfahren zur Herstellung von Diarylcarbonaten und den daraus erhältlichen Polycarbonaten
DE59007794D1 (de) Verfahren zur Herstellung von 2-Chlor-5-chlormethyl-pyridin und neue Zwischenprodukte.
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
ATE297211T1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DE59907958D1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee